NCT06432036 - Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 26, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 30, 2027

Conditions

Stage I Renal Cell CancerStage II Renal Cell Cancer

Interventions

PROCEDURE

Angiogram

Undergo angiogram

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

RADIATION

Radioembolization

Undergo radioembolization

PROCEDURE

Single Photon Emission Computed Tomography

Undergo SPECT

OTHER

Survey Administration

Ancillary study

RADIATION

Yttrium Y 90 Glass Microspheres

Given intra-arterially

Trial Locations (1)

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles